Skip to main content
THERAGEN ETEX CO.,LTD. logo

THERAGEN ETEX CO.,LTD. — Investor Relations & Filings

Ticker · 066700 ISIN · KR7066700006 KO Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2025-12-30 Earnings Release
Country KR South Korea
Listing KO 066700

About THERAGEN ETEX CO.,LTD.

http://www.theragenetex.com/

THERAGEN ETEX CO.,LTD. is a biotechnology and pharmaceutical group focused on genome-based personalized and precision medicine. The company integrates advanced genomic analysis with pharmaceutical development and manufacturing. Its genomics division provides comprehensive genetic analysis services, leveraging pioneering achievements such as creating the world's first female and tiger genome maps and commercializing Asia's first individual genome analysis service. The pharmaceutical division develops and supplies medicines from its international GMP-certified facilities. The R&D pipeline focuses on incrementally modified drugs, orphan drugs, and novel anticancer therapies, including its proprietary drug candidate, Vactosertib, which is in clinical trials for various cancers.

Recent filings

Filing Released Lang Actions
[기재정정]영업실적등에대한전망(공정공시)
Earnings Release Classification · 95% confidence The document is a regulatory filing from Teragen Etex regarding a revision of their previously announced earnings forecast (Fair Disclosure). It provides updated revenue and operating profit projections for the 2025 fiscal year and explains the reasons for the revision. Since this is a formal regulatory announcement of financial projections rather than a full quarterly report or an earnings release, it falls under the category of general regulatory filings. FY 2025
2025-12-30 Korean
전환가액의조정
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the adjustment of the conversion price of convertible bonds (전환가액의 조정) for a specific issuance (10th series). It includes specific financial figures such as the adjusted conversion price, the number of convertible shares before and after adjustment, the reason for adjustment (price decline), and the method of calculation. It also mentions the application date of the adjusted price and notes that there was no board resolution as it is a price adjustment due to market price decline. This type of document is a capital/financing update related to convertible bonds and their terms, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive financial data and detailed adjustment methodology. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-10-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It includes detailed information about the ownership of securities by an executive named 박 시 홍, including the number of shares owned, changes in ownership, and types of securities held. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a formal notification of share ownership changes by insiders. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 2467 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2025-10-20 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Theragen Etex, covering the period from January 1, 2025, to June 30, 2025. It contains comprehensive financial and operational data, including company overview, business activities, capital structure, and production details. As it is a comprehensive financial report for a period shorter than a full fiscal year (half-year) and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Teragen Etex, detailing quarterly financial performance (revenue, operating profit, net income) for Q2 2025. It provides key financial highlights and is explicitly labeled as a preliminary report subject to change, which fits the definition of an Earnings Release (ER). Q2 2025
2025-07-30 Korean
영업실적등에대한전망(공정공시)
Management Reports Classification · 100% confidence The document is a 'Fair Disclosure' (공정공시) filing from Teragen Etex regarding their projected financial performance (sales and operating profit) for the 2025 fiscal year. This type of regulatory filing, which provides forward-looking guidance on financial results, is classified as a general regulatory announcement under the RNS category as it does not constitute a full earnings release, interim report, or management report, but rather a specific regulatory disclosure of projections.
2025-07-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.